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Prophylaxis in inhibitor patients was first described in the mid 1970s. Emerging data 
from clinical trials suggests that all bleeding episodes, joint bleeds in particular,  
can be significantly reduced in many patients with inhibitors through the regular use 
of bypassing agents (BPA). In our center there are three patients under secondary 
prophylaxis with BPA. These patients began prophylaxis with aPCC after severe and 
recurrent bleeds, including life-threatening episodes. 
The most striking findings over the last six years of experience with BPA are the absence 
of life-threatening bleeding episodes and reduced inpatient stays or emergency 
room visits, as well as significant improvement in quality of life. One patient also 
experienced a significant reduction in frequency of all bleeds. 
Our study indicates that aPCC prophylaxis at a dose of 50-70 UI/Kg administered on 
2 non-consecutive days a week decreases life-threatening bleeds and may decrease 
overall bleeding. No adverse effects were detected. 
Regarding our actual economic constraints, one may say that the cost of BPA can  
be a real limitation. But the potential benefits of avoiding hospitalizations and days lost  
from school or work, and the prevention of long term complications, make this 
treatment a real option.
We reviewed the medical records of three adults with severe hemophilia A with inhibitors 
on prophylactic treatment with activated prothrombin complex concentrate (aPCC) at our 
center.
Our aim was to measure the efficacy of prophylactic treatment by demonstrating a 
significant reduction in all bleeding events during a period of prophylaxis compared to the 
previous on-demand period. The quality of life (QoL) of our patients was also assessed 
by their ability to participate in normal daily activities.
After exposure to FVIII, alloantibodies that neutralize FVIII clotting function develop  
in approximately 30% of patients with severe hemophilia A. Although most patients 
with inhibitors do not bleed more frequently than patients without inhibitors, hemorrhagic 
complications are severe, bleeding is more difficult to control and patients have 
higher morbidity and mortality. 
Prophylaxis treatment is the standard of care for patients who have severe hemophilia 
A without inhibitors, and its benefits could be extended to inhibitor patients.
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Patient 1  
Patient 2  
Patient 3  
32 year old patient, high responder, usually receiving 
on-demand treatment with either aPCC or recombinant 
FVIIa. Prophylaxis with aPCC (70 IU/Kg BIW) was 
started in 2008, after five consecutive severe muscle 
bleeds led to hospitalization. In the prophylactic 
period the bleeding events reduced by 80% without 
any hospitalizations or emergency room visits. The 
improvement in patient QoL was significant resulting in 
the restoration of his normal daily activities. 
45 year old patient, high responder, usually receiving 
on-demand treatment with either aPCC or recombinant 
FVIIa. Prophylaxis with aPCC (50-60 IU/Kg BIW) was 
started after a life-threatening intra-abdominal bleed 
in 2006. On prophylaxis, the observed reduction in 
overall bleeding events was 43%. This patient also had 
a significant improvement in his QoL, with reduced 
absence from work.  
50 year old patient, high responder, with a bleeding 
pseudotumor in the right tibia. Taking a conservative 
approach to this complication, prophylaxis with aPCC 
(55 IU/Kg BIW) was started in 2012 after failed ITI. In 
this setting, the patient remained asymptomatic with no 
further bleeds. There was no change in the frequency  
of all other bleeds.
